AIM (AIM ImmunoTech Inc.) Stock Analysis - SEC Filings

AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of May 21, 2026, AIM trades at $0.26 with a market cap of $6.36M and a P/E ratio of -0.05. AIM moved -38.69% today. Year to date, AIM is -80.10%; over the trailing twelve months it is +102.64%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find AIM SEC filings?

Rallies organizes AIM SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

AIM Key Metrics

Key financial metrics for AIM
MetricValue
Price$0.26
Market Cap$6.36M
P/E Ratio-0.05
EPS$-8.62
Dividend Yield0.00%
52-Week High$20.33
52-Week Low$0.06
Volume11.72M
Avg Volume0
Revenue (TTM)$88.00K
Net Income$-13.96M
Gross Margin0.00%

Latest AIM News

Recent AIM Insider Trades

  • Equels Thomas K bought 107 (~$823.579) on Jun 13, 2025.
  • Equels Thomas K bought 103 (~$896.1) on Jun 12, 2025.
  • MITCHELL WILLIAM M bought 196.85K (~$5.00K) on Apr 11, 2025.

AIM Analyst Consensus

1 analysts cover AIM: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.

Common questions about AIM

Where can I find AIM SEC filings?
Rallies organizes AIM SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show AIM 10-K and 10-Q filings?
Rallies organizes AIM SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is AIM research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AIM. It does not provide personalized investment advice.
AIM

AIM